Survival and risk of leukemic evolution of patients with MDS classified according to the clusters resulting from the unsupervised analysis including WHO classification criteria and mutation patterns. (A) Overall survival and (B) risk of AML evolution of MDS patients clustered as follows: MDS associated with SF3B1 mutation; MDS with MD–associated mutations; MDS NOS; and MDS with excess blasts (RAEB).